奥美拉唑合成用于质子泵抑制剂

用手性选择化学控制胃酸

Pharmaceutical & Drug Manufacturing Global Industrial Scale $3.5 billion

概述

Omeprazole is the first proton pump inhibitor (PPI) to reach the market and remains one of the most prescribed medications globally for treating gastric acid disorders, peptic ulcers, and GERD. The synthesis involves a multi-step process building the benzimidazole-pyridine core structure. The chiral version, esomeprazole (the S-enantiomer), represents a significant pharmaceutical advancement, produced using an asymmetric oxidation that won AstraZeneca substantial patent protection.

化学工艺

2-Chloromethyl-3,5-dimethyl-4-methoxypyridine is coupled with 5-methoxy-2-mercaptobenzimidazole to form the thioether intermediate. Selective oxidation with m-CPBA or titanium-mediated asymmetric oxidation yields the sulfoxide drug substance.

Thioether intermediate + m-CPBA → Omeprazole (sulfoxide)
For esomeprazole: Ti(OiPr)₄/(R,R)-DET/cumene hydroperoxide → S-omeprazole (>99.5% ee)

原材料

  • 5-Methoxy-2-mercaptobenzimidazole — Multi-step synthesis from o-phenylenediamine (Core structure)
  • 2-Chloromethyl-3,5-dimethyl-4-methoxypyridine — Pyridine chemistry (Pyridine moiety)
  • m-CPBA (meta-chloroperoxybenzoic acid) — Chemical synthesis (Oxidizing agent)

最终产品

  • Omeprazole (C₁₇H₁₉N₃O₃S) — Proton pump inhibitor for GERD and ulcers (Racemic or enantiopure form)
<path stroke-linecap="round" stroke-linejoin="round" d="M12 9v3.75m-9.303 3.376c-.866 1.5.217 3.374 1.948 3.374h14.71c1.73 0 2.813-1.874 1.948-3.374L13.949 3.378c-.866-1.5-3.032-1.5-3.898 0L2.697 16.126zM12 15.75h.007v.008H12v-.008z" />

Environmental Impact

Multi-step synthesis generates significant organic waste including halogenated solvents. m-CPBA oxidation produces m-chlorobenzoic acid waste. Modern production increasingly uses catalytic oxidation methods and solvent recycling to minimize environmental impact.

安全注意事项

最新创新

Biocatalytic oxidation using engineered cytochrome P450 enzymes and Baeyer-Villiger monooxygenases offers enantioselective sulfoxidation under mild conditions, potentially replacing chemical oxidants entirely.

生产规模

800

吨/年

$3.5 billion

市场价值

更多 Pharmaceutical & Drug Manufacturing

发酵法生产青霉素G

Global Industrial Scale

布洛芬合成——BHC绿色工艺

Global Industrial Scale

扑热息痛（对乙酰氨基酚）合成

Global Industrial Scale

水杨酸乙酰化合成阿司匹林

Global Industrial Scale

盐酸二甲双胍合成

Global Industrial Scale

重组人胰岛素生产

Global Industrial Scale

阿莫西林半合成生产

Global Industrial Scale

Frequently Asked Questions

What industry uses 奥美拉唑合成用于质子泵抑制剂?
奥美拉唑合成用于质子泵抑制剂 is used in the pharmaceutical & drug manufacturing sector at global industrial scale scale.
What process is involved in 奥美拉唑合成用于质子泵抑制剂?
2-Chloromethyl-3,5-dimethyl-4-methoxypyridine is coupled with 5-methoxy-2-mercaptobenzimidazole to form the thioether intermediate. Selective oxidation with m-CPBA or titanium-mediated asymmetric oxidation yields the sulfoxide drug substance.
What is the economic significance of 奥美拉唑合成用于质子泵抑制剂?
奥美拉唑合成用于质子泵抑制剂 has a market value of $3.5 billion and annual production of 800 tons.
What is the environmental impact of 奥美拉唑合成用于质子泵抑制剂?
Multi-step synthesis generates significant organic waste including halogenated solvents. m-CPBA oxidation produces m-chlorobenzoic acid waste. Modern production increasingly uses catalytic oxidation methods and solvent recycling to minimize environmental impact.
What raw materials are used in 奥美拉唑合成用于质子泵抑制剂?
The main raw materials include: 5-Methoxy-2-mercaptobenzimidazole, 2-Chloromethyl-3,5-dimethyl-4-methoxypyridine, m-CPBA (meta-chloroperoxybenzoic acid).